Morgan Stanley’s Nasus Pharma NSRX Stock Holding History

Morgan Stanley’s Portfolio NSRX Stock Details NSRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.44K	Hold	2,000	–	–	﹤0.01%	7170
2025 Q4	$18.3K	Hold	2,000	–	–	﹤0.01%	6718
2025 Q3	$13.3K	Buy	+2,000	New	+$16.1K	﹤0.01%	6817

Other funds holding NSRX

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley's NSRX Position: Q1 2026 in Review

Morgan Stanley held its Nasus Pharma (NSRX) position steady in Q1 2026 at 2,000 shares worth $4.44K. The position accounts for ﹤0.01% of the portfolio, ranked #7170.

Morgan Stanley first reported a position in NSRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $18.3K in Q4 2025. 9 funds tracked by Wall St. Rank hold NSRX as of Q1 2026.

Morgan Stanley held 2,000 shares of Nasus Pharma worth $4.44K as of Q1 2026.
Morgan Stanley left its Nasus Pharma share count unchanged in Q1 2026.
Nasus Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7170 holding.
Morgan Stanley first reported a position in Nasus Pharma in Q3 2025 and has held it in 3 quarters since.
Morgan Stanley's Nasus Pharma position peaked at $18.3K in Q4 2025.
9 funds tracked by Wall St. Rank held Nasus Pharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.